• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外研究达氟沙星对高度左氧氟沙星耐药的侵袭性肺炎链球菌分离株的活性。

In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae.

机构信息

Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Departamento de Medicina, Facultad de Medicina, Universidad Complutense, Madrid, Spain.

Laboratorio de Microbiología, Hospital Santa Bárbara, Puertollano (Ciudad Real), Spain.

出版信息

Enferm Infecc Microbiol Clin (Engl Ed). 2022 Mar;40(3):131-133. doi: 10.1016/j.eimce.2020.09.009.

DOI:10.1016/j.eimce.2020.09.009
PMID:35249673
Abstract

INTRODUCTION

We report the activity of delafloxacin, a new fluoroquinolone with high affinity for both topoisomerase IV and DNA gyrase, against highly-levofloxacin-resistant invasive strains of Streptococcus pneumoniae.

METHODS

A total of 173 highly-levofloxacin-resistant (MIC>32mg/L) S. pneumoniae invasive isolates were studied. The strains were isolated from blood (n=162) and other sterile fluids (n=11). Serotyping was performed by the Pneumotest-Latex and Quellung reaction. Delafloxacin, levofloxacin, penicillin, cefotaxime, erythromycin and vancomycin MICs were determined by the gradient diffusion method following EUCAST guidelines and breakpoints.

RESULTS

Among the isolates, 32.9% were penicillin non-susceptible, 19.7% cefotaxime non-susceptible, and 76.9% erythromycin resistant. All were susceptible to vancomycin. Delafloxacin MIC and MIC (mg/L) values were 0.064 and 0.12, respectively; 60% (15/25) of serotype 9V isolates showed delafloxacin MICs≥0.12mg/L.

CONCLUSIONS

Delafloxacin was very active against highly-levofloxacin-resistant invasive isolates of S. pneumoniae. Isolates belonging to serotype 9V showed higher delafloxacin MIC values.

摘要

简介

我们报告了德拉沙星的活性,这是一种新型氟喹诺酮类药物,对拓扑异构酶 IV 和 DNA 回旋酶具有高亲和力,针对高度耐左氧氟沙星的侵袭性肺炎链球菌株。

方法

共研究了 173 株高度耐左氧氟沙星(MIC>32mg/L)的肺炎链球菌侵袭性分离株。这些菌株是从血液(n=162)和其他无菌体液(n=11)中分离出来的。血清分型采用 Pneumotest-Latex 和 Quellung 反应进行。根据 EUCAST 指南和折点,采用梯度扩散法测定德拉沙星、左氧氟沙星、青霉素、头孢噻肟、红霉素和万古霉素的 MIC。

结果

在分离株中,32.9%对青霉素不敏感,19.7%对头孢噻肟不敏感,76.9%对红霉素耐药。所有菌株均对万古霉素敏感。德拉沙星 MIC 和 MIC(mg/L)值分别为 0.064 和 0.12,60%(15/25)的 9V 血清型分离株显示德拉沙星 MIC≥0.12mg/L。

结论

德拉沙星对高度耐左氧氟沙星的侵袭性肺炎链球菌分离株非常有效。属于血清型 9V 的分离株显示出更高的德拉沙星 MIC 值。

相似文献

1
In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae.体外研究达氟沙星对高度左氧氟沙星耐药的侵袭性肺炎链球菌分离株的活性。
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Mar;40(3):131-133. doi: 10.1016/j.eimce.2020.09.009.
2
In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae.达氟沙星对高度耐左氧氟沙星的侵袭性肺炎链球菌分离株的体外活性
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Nov 12. doi: 10.1016/j.eimc.2020.09.016.
3
Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae.单独使用和联合使用头孢噻肟治疗头孢噻肟不敏感的侵袭性肺炎链球菌分离株的疗效。
Rev Esp Quimioter. 2024 Apr;37(2):158-162. doi: 10.37201/req/107.2023. Epub 2024 Jan 16.
4
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.针对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌分离株检测的德拉氟沙星的体外活性
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.
5
Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Species.达氟沙星和萘甲唑啉对支原体和其他种属的活性。
Microbiol Spectr. 2022 Jun 29;10(3):e0009922. doi: 10.1128/spectrum.00099-22. Epub 2022 May 9.
6
Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.两项急性细菌性皮肤和皮肤结构感染 3 期研究中分离的氟喹诺酮敏感和不敏感金黄色葡萄球菌分离株的达托霉素活性和微生物学应答。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00772-17. Print 2017 Sep.
7
Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.地拉氟沙星与对照药物对参与骨关节炎感染的表皮葡萄球菌临床菌株的体外活性比较:一项CRIOGO多中心回顾性研究。
J Antimicrob Chemother. 2024 May 2;79(5):1045-1050. doi: 10.1093/jac/dkae071.
8
In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.体外研究左氧氟沙星耐药幽门螺杆菌临床分离株对德拉沙星的活性。
J Antimicrob Chemother. 2024 Oct 1;79(10):2633-2639. doi: 10.1093/jac/dkae269.
9
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.在小鼠肺部感染模型中对达氟沙星针对金黄色葡萄球菌、肺炎链球菌和肺炎克雷伯菌的体内药效学靶点评估
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9. doi: 10.1128/AAC.00647-16. Print 2016 Aug.
10
In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.左氧氟沙星及其他三种氟喹诺酮类药物对青霉素敏感和耐药肺炎链球菌的体外抑菌活性
J Antimicrob Chemother. 1999 Jun;43 Suppl C:9-14. doi: 10.1093/jac/43.suppl_3.9.

引用本文的文献

1
Genetic Mechanisms of Antimicrobial Non-Susceptibility to Novel Fluoroquinolone Delafloxacin Among Bulgarian Clinical Isolates of .保加利亚临床分离株中对新型氟喹诺酮类药物德拉氟沙星抗菌不敏感的遗传机制
Curr Issues Mol Biol. 2025 Jun 11;47(6):446. doi: 10.3390/cimb47060446.
2
Structural basis of topoisomerase targeting by delafloxacin.达氟沙星作用于拓扑异构酶的结构基础
Nat Commun. 2025 Jul 1;16(1):5829. doi: 10.1038/s41467-025-60688-3.
3
Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae.
单独使用和联合使用头孢噻肟治疗头孢噻肟不敏感的侵袭性肺炎链球菌分离株的疗效。
Rev Esp Quimioter. 2024 Apr;37(2):158-162. doi: 10.37201/req/107.2023. Epub 2024 Jan 16.
4
Updated Review on Clinically-Relevant Properties of Delafloxacin.关于德拉氟沙星临床相关特性的最新综述
Antibiotics (Basel). 2023 Jul 28;12(8):1241. doi: 10.3390/antibiotics12081241.